

Meeting Expectations with Steady Growth- Trend to Continue

https://marketpublishers.com/r/M4C33AACDE8EN.html

Date: October 2011 Pages: 5 Price: US\$ 90.00 (Single User License) ID: M4C33AACDE8EN

Abstracts

Soliris uptake in patients for Paroxysmal Nocturnal Hemoglobinuria (PNH) and accelerated approval in atypical Hemolytic Uremic Syndrome (aHUS) validate the long term potential of the drug. In upcoming scientific conference American Society of Nephrology (Nov. 8th to 13th) ALXN will present multiple data, showing potential of eculizumab in other indications targeting rare and high unmet need along with approved indication... For more details, please read our report released on October 21, 2011 on Alexion (ALXN), titled "Meeting Expectations with Steady Growth- Trend to Continue".



Contents

COMPANIES MENTIONED

Alexion, Biogen Idec, Celgene, Gilead



I would like to order

Product name: Meeting Expectations with Steady Growth- Trend to Continue Product link: <u>https://marketpublishers.com/r/M4C33AACDE8EN.html</u>

Price: US\$ 90.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/M4C33AACDE8EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970